Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1·36%<sup>®</sup>and Dianeal PD1 3·86%<sup>®</sup>)

Fernández-Varón, Emilio; Marı́n, Pedro; Espuny, A; Villamayor, L.; Escudero, Elisa; Cárceles, C. M.

doi:10.1111/j.1365-2710.2006.00758.x

Cited by 8 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…141 In other words, avoiding prolonged aminoglycoside should be advocated to prevent aminoglycoside ototoxicity. Fluoroquinolones, including ciprofloxacin 266 and moxifloxacin, 267 have been confirmed to be compatible with PD solutions and shown to be highly active and bactericidal in PD fluids with concentration-dependent activity. 268 A small randomised controlled study supported the safety and efficacy of IP vancomycin plus oral moxifloxaicin but was not powered to be a non-inferiority trial.…”

Section: Dosage Of Antibioticsmentioning

confidence: 99%

ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment

et al. 2022

View full text Add to dashboard Cite

Peritoneal dialysis (PD)-associated peritonitis is a serious complication of PD and prevention and treatment of such is important in reducing patient morbidity and mortality. The ISPD 2022 updated recommendations have revised and clarified definitions for refractory peritonitis, relapsing peritonitis, peritonitis-associated catheter removal, PD-associated haemodialysis transfer, peritonitis-associated death and peritonitis-associated hospitalisation. New peritonitis categories and outcomes including pre-PD peritonitis, enteric peritonitis, catheter-related peritonitis and medical cure are defined. The new targets recommended for overall peritonitis rate should be no more than 0.40 episodes per year at risk and the percentage of patients free of peritonitis per unit time should be targeted at >80% per year. Revised recommendations regarding management of contamination of PD systems, antibiotic prophylaxis for invasive procedures and PD training and reassessment are included. New recommendations regarding management of modifiable peritonitis risk factors like domestic pets, hypokalaemia and histamine-2 receptor antagonists are highlighted. Updated recommendations regarding empirical antibiotic selection and dosage of antibiotics and also treatment of peritonitis due to specific microorganisms are made with new recommendation regarding adjunctive oral N-acetylcysteine therapy for mitigating aminoglycoside ototoxicity. Areas for future research in prevention and treatment of PD-related peritonitis are suggested.

show abstract

Section: Dosage Of Antibioticsmentioning

confidence: 99%

ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fernandez-Varon et al . [ 88 ] investigated the stability of IP moxifloxacin 25 mg/L in two glucose-based PD solutions (Dianeal PD-1 1.36% and 3.86% glucose). In Dianeal PD-1 1.36% glucose solution, > 95% initial moxifloxacin concentration was retained for 14 days at 4 °C and 7 days at 25 °C.…”

Section: Discussionmentioning

confidence: 99%

Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility

Ling,

Sud,

Patel

et al. 2023

J Nephrol

View full text Add to dashboard Cite

Background This systematic review summarises the stability of less commonly prescribed antibiotics in different peritoneal dialysis solutions that could be used for culture-directed therapy of peritonitis, which would be especially useful in regions with a high prevalence of multidrug antibiotic-resistant strains. Methods A literature search of Medline, Scopus, Embase and Google Scholar for articles published from inception to 25 January, 2023 was conducted. Only antibiotic stability studies conducted in vitro and not recently reviewed by So et al. were included. The main outcomes were chemical, physical, antimicrobial and microbial stability. This protocol was registered in PROSPERO (registration number CRD42023393366). Results We screened 1254 abstracts, and 28 articles were included in the study. In addition to those discussed in a recent systematic review (So et al., Clin Kidney J 15(6):1071–1078, 2022), we identified 18 antimicrobial agents. Of these, 9 have intraperitoneal dosing recommendations in the recent International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines, and 7 of the 9 had stability data applicable to clinical practice. They were cefotaxime, ceftriaxone, daptomycin, ofloxacin, and teicoplanin in glucose-based solutions, tobramycin in Extraneal solution only and fosfomycin in Extraneal, Nutrineal, Physioneal 1.36% and 2.27% glucose solutions. Conclusions Physicochemical stability has not been demonstrated for all antibiotics with intraperitoneal dosing recommendations in the ISPD peritonitis guidelines. Further studies are required to determine the stability of antibiotics, especially in icodextrin-based and low-glucose degradation products, pH-neutral solutions. Graphical abstract

show abstract

“…If quinolone is used for Pseudomonas peritonitis , however, ciprofloxacin should be used instead because moxifloxacin has very little anti-pseudomonal activity. Moxifloxacin remains stable in 1.36 and 3.86% dextrose PDF [ 77 ]. There is no dosage recommendation for IP use.…”

Section: Moxifloxacinmentioning

confidence: 99%

Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis

et al. 2016

View full text Add to dashboard Cite

Peritonitis is a debilitating infectious complication of peritoneal dialysis (PD). Drug-resistant bacterial peritonitis typically has a lower response rate to antibiotics. In the past 15 years, newer antibiotics with activities against drug-resistant Gram-positive bacteria have been developed. In most circumstances, peritonitis due to methicillin-resistant staphylococci responds to vancomycin. If vancomycin cannot be used due to allergy and/or non-susceptibility, there is increasing evidence that linezolid and daptomycin are the drugs of choice. It is reasonable to start linezolid orally or intravenously, but subsequent dose reduction may be necessary in case of myelosuppression. Daptomycin can be given intravenously or intraperitoneally and has excellent anti-biofilm activity. Other treatment options for drug-resistant Gram-positive bacterial peritonitis include teicoplanin, tigecycline and quinupristin/dalfopristin. Teicoplanin is not available in some countries (e.g. the USA). Tigecycline can only be given intravenously. Quinupristin/dalfopristin is ineffective against Enterococcus faecalis and there is only low-quality evidence to support its efficacy in the treatment of peritonitis. Effective newer antibiotics against drug-resistant Gram-negative bacteria are lacking. Polymyxins can be considered, but evidence on its efficacy is limited. In this review, we will discuss the potential use of newer antibiotics in the treatment of drug-resistant bacterial peritonitis in PD patients.

show abstract

Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1·36%^®and Dianeal PD1 3·86%^®)

Abstract: Moxifloxacin shows sufficient stability in both PD bags for use in PD patients.

Cited by 8 publications

References 10 publications

ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment

ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment

Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility

Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis

Contact Info

Product

Resources

About

Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1·36%®and Dianeal PD1 3·86%®)

Abstract: Moxifloxacin shows sufficient stability in both PD bags for use in PD patients.

Cited by 8 publications

References 10 publications

ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment

ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment

Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility

Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis

Contact Info

Product

Resources

About

Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1·36%^®and Dianeal PD1 3·86%^®)